A Short Biography:
Dr. Ghosh is an Associate Professor of Ophthalmology at UCLA and a Principal Investigator at the Doheny Eye Institute. His vascular mechanobiology lab aims to integrate the principles of biology and engineering to develop effective therapies for vision-threatening diseases, specifically diabetic retinopathy (DR) and age-related macular degeneration (AMD). His research has been funded by extramural grants from the National Institutes of Health (NIH), BrightFocus Foundation, and Hellman Foundation. Prior to joining UCLA and the Doheny Eye Institute in 2019, he was an Associate Professor of Bioengineering at UC Riverside. Prof. Ghosh did his postdoctoral training in vascular mechanobiology at Boston Children’s Hospital and Harvard Medical School, received his Ph.D. in Biomedical Engineering from Stony Brook University, and obtained his undergraduate degree in Chemical Engineering from National Institute of Technology, Warangal, India.
Our research aims to understand the mechanobiology of vascular inflammation and degeneration in eye diseases, specifically diabetic retinopathy (DR) and age-related macular degeneration (AMD). Currently, DR and AMD are clinically managed only in their advanced stages that are marked by excessive multiplication and leakiness of blood vessels in the inner and outer retina, respectively. However, there is growing recognition that more effective treatment of these conditions is possible by tackling them in the early stages when these blood vessels degenerate. We are taking a multidisciplinary approach to understand and prevent this early loss of blood vessels in diabetes and aging. Integrating the principles of vascular biology, mechanobiology, inflammation, and bioengineering, our work has introduced a new paradigm that implicates vascular 'stiffness' as a crucial determinant of vascular degeneration associated with early DR and AMD. Our ongoing studies aim to identify the factors that alter vascular stiffness in the eye and uncover the mechanobiological mechanisms by which altered stiffness causes vascular loss in diabetes and aging. These studies, performed in collaboration with ophthalmologists and funded by the National Eye Institute/NIH, have the potential to identify new classes of drugs that restore normal vascular stiffness and function in the eye and thereby block DR and AMD progression in their early stages.
A selected list of publications:
Yang Xiao, Scott Harry A, Monickaraj Finny, Xu Jun, Ardekani Soroush, Nitta Carolina F, Cabrera Andrea, McGuire Paul G, Mohideen Umar, Das Arup, Ghosh Kaustabh
Basement membrane stiffening promotes retinal endothelial activation
associated with diabetes
FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Adini Irit, Ghosh Kaustabh, Adini Avner, Chi Zai-Long, Yoshimura Takeru, Benny Ofra, Connor Kip M, Rogers Michael S, Bazinet Lauren, Birsner Amy E, Bielenberg Diane R, D'Amato Robert J
Melanocyte-secreted fibromodulin promotes an angiogenic
The Journal of clinical investigation,